BRPI0610132B8 - composição farmacêutica, kit e utilização de uma composição - Google Patents

composição farmacêutica, kit e utilização de uma composição

Info

Publication number
BRPI0610132B8
BRPI0610132B8 BRPI0610132A BRPI0610132A BRPI0610132B8 BR PI0610132 B8 BRPI0610132 B8 BR PI0610132B8 BR PI0610132 A BRPI0610132 A BR PI0610132A BR PI0610132 A BRPI0610132 A BR PI0610132A BR PI0610132 B8 BRPI0610132 B8 BR PI0610132B8
Authority
BR
Brazil
Prior art keywords
composition
pharmaceutical composition
kit
pharmaceutical
ionone
Prior art date
Application number
BRPI0610132A
Other languages
English (en)
Portuguese (pt)
Inventor
Remmal Adnane
Original Assignee
Advanced Scient Developments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developments filed Critical Advanced Scient Developments
Publication of BRPI0610132A2 publication Critical patent/BRPI0610132A2/pt
Publication of BRPI0610132B1 publication Critical patent/BRPI0610132B1/pt
Publication of BRPI0610132B8 publication Critical patent/BRPI0610132B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0610132A 2005-05-13 2006-05-15 composição farmacêutica, kit e utilização de uma composição BRPI0610132B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2005/001317 2005-05-13
PCT/IB2005/001317 WO2006120496A1 (fr) 2005-05-13 2005-05-13 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol
PCT/IB2006/001329 WO2006120565A2 (fr) 2005-05-13 2006-05-15 Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l'eugenol, le thymol, le borneol, le carvacrol, et les i0n0nes alpha- et beta-.

Publications (3)

Publication Number Publication Date
BRPI0610132A2 BRPI0610132A2 (pt) 2012-09-25
BRPI0610132B1 BRPI0610132B1 (pt) 2020-08-11
BRPI0610132B8 true BRPI0610132B8 (pt) 2021-05-25

Family

ID=35427301

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0610132A BRPI0610132B8 (pt) 2005-05-13 2006-05-15 composição farmacêutica, kit e utilização de uma composição

Country Status (13)

Country Link
US (1) US20080214568A1 (enExample)
EP (1) EP1879654B1 (enExample)
JP (1) JP5410747B2 (enExample)
CN (1) CN101189044B (enExample)
BR (1) BRPI0610132B8 (enExample)
CA (1) CA2607561C (enExample)
DK (1) DK1879654T3 (enExample)
EA (1) EA014068B1 (enExample)
ES (1) ES2390472T3 (enExample)
MA (1) MA29907B1 (enExample)
PT (1) PT1879654E (enExample)
TN (1) TNSN07425A1 (enExample)
WO (2) WO2006120496A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2581507C (en) 2004-09-28 2013-09-10 Chemaphor Inc. Compositions and methods for promoting weight gain and feed conversion
ES2716474T3 (es) 2007-10-26 2019-06-12 Avivagen Inc Composiciones y métodos para mejorar la respuesta inmunitaria
WO2010124391A1 (en) 2009-04-30 2010-11-04 Chemaphor Inc. Methods and compositions for improving the health of animals
EA019746B1 (ru) 2009-09-24 2014-05-30 Юнилевер Нв Противомикробная композиция, содержащая эвгенол, терпинеол и тимол, и способ дезинфицирования поверхности
CN103354741B (zh) 2010-12-07 2016-01-13 荷兰联合利华有限公司 口腔护理组合物
CN102550610B (zh) * 2010-12-07 2014-12-10 菲勒斯株式会社 含有从红松球果中提取的植物杀菌素的天然抗菌剂及包含它的水果病害防除原料
EP2672845A2 (en) * 2011-02-07 2013-12-18 Firmenich SA Antifungal flavouring ingredients and compositions
EP2773315B1 (en) 2011-11-03 2015-07-08 Unilever N.V. A personal cleaning composition
JP5925605B2 (ja) * 2012-06-04 2016-05-25 花王株式会社 リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
IL251588B2 (en) 2014-10-08 2024-09-01 Pacific Northwest Res Institute Methods and compositions for increasing the potency of antifungal agents
CN104642326B (zh) * 2015-02-16 2016-02-10 河南科技学院 一种含戊苯吡菌胺和香芹酚的杀菌组合物及其用途
US11872216B2 (en) 2016-06-02 2024-01-16 Advanced Scientific Developments Pharmaceutical formulation comprising cineole and amoxicillin
ES2937307T3 (es) 2016-07-26 2023-03-27 Univ Southern California Inhibición selectiva del bromodominio del BDF1 fúngico
CN113116916B (zh) * 2021-05-25 2023-07-04 河北医科大学第二医院 一种治疗妇科疾病的药物组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294645A (en) * 1993-06-14 1994-03-15 Doyle E. Chastain Using menth-1-en-9-ol to kill bacteria, yeast, and fungi
CA2106032C (en) * 1993-09-13 1995-11-07 Gamini Weeratunga Methods for the manufacture of fluconazole and forms thereof, intermediates useful in the manufacture thereof, and combinations comprising fluconazole
ATE215379T1 (de) * 1994-01-14 2002-04-15 Xoma Technology Ltd Antifungaleverfahren und mitteln
US5916566A (en) * 1995-06-07 1999-06-29 Avmax, Inc. Use of benzoin gum to inhibit P-glycoprotein-mediated resistance of pharmaceutical compounds
US6319507B1 (en) * 1997-05-02 2001-11-20 Kobo Products, Inc. Agar gel bead composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
WO2002056879A1 (en) * 2001-01-03 2002-07-25 Medpharma Plc Use of terpenes for the treatment of digestive tract infections
JP2002284702A (ja) * 2001-01-19 2002-10-03 Teika Seiyaku Kk 外用抗真菌製剤
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
JP2002363070A (ja) * 2001-06-06 2002-12-18 Yuutoku Yakuhin Kogyo Kk 経皮吸収貼付剤
US20040071757A1 (en) * 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
EP1455768A1 (en) * 2001-12-07 2004-09-15 Eden Research Plc Respiratory infection prevention and treatment with terpene-containing compositions
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US20050014730A1 (en) * 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil

Also Published As

Publication number Publication date
CA2607561C (fr) 2014-02-04
ES2390472T3 (es) 2012-11-13
BRPI0610132A2 (pt) 2012-09-25
JP5410747B2 (ja) 2014-02-05
WO2006120565A3 (fr) 2007-08-23
WO2006120496A1 (fr) 2006-11-16
US20080214568A1 (en) 2008-09-04
BRPI0610132B1 (pt) 2020-08-11
MA29907B1 (fr) 2008-11-03
CA2607561A1 (fr) 2006-11-16
EP1879654A2 (fr) 2008-01-23
DK1879654T3 (da) 2012-08-20
TNSN07425A1 (fr) 2009-03-17
WO2006120565A2 (fr) 2006-11-16
EA014068B1 (ru) 2010-08-30
EP1879654B1 (fr) 2012-07-04
CN101189044B (zh) 2011-12-07
CN101189044A (zh) 2008-05-28
PT1879654E (pt) 2012-08-29
EA200702482A1 (ru) 2008-04-28
JP2008540506A (ja) 2008-11-20

Similar Documents

Publication Publication Date Title
BRPI0610125B8 (pt) composição farmacêutica, kit e utilização de uma composição
BRPI0610132B8 (pt) composição farmacêutica, kit e utilização de uma composição
CL2007002641A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
PE20091394A1 (es) Un compuesto de alfa-(n-sulfonamido) acetamida con un inhibidor de produccion de peptido beta amiloide
CL2008000593A1 (es) Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.
BR122018014454B8 (pt) forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
GT200900057A (es) 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridina-2-carboxamida monohidrato
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
UY29983A1 (es) Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis
CL2007002197A1 (es) Compuestos derivados de indol; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes mellitus, retinopatia diabetica, hiperglucemia, hiperl
CL2010001526A1 (es) Compuestos derivados de isonicotinamida, moduladores de la estearoil-coa-desaturasa; composicion farmaceutica que comprende un compuesto;utiles para tratar enfermedades relacionadas con dislipidemia y trastornos del metabolismo de lipidos.
MX384206B (es) Formulaciones de inhibidores de dpp iv
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
CL2007002187A1 (es) Compuestos derivados espirocetal sustituidos; composicion farmaceutica que comprende a dicho compuesto; y su uso para el tratamiento de la diabetes, hiperglicemia, complicaciones diabeticas y obesidad.
HN2006000971A (es) Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
BRPI0513812B8 (pt) método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical
BRPI0618380A2 (pt) combinação farmacêutica e seu uso
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
GT200500309A (es) Derivados de sulfonilbencilimidazol
EA200702486A1 (ru) Противовирусная, противоопухолевая или противопаразитарная фармацевтическая композиция и ее применение
UY31788A (es) Formulación farmacéutica sólida con liberación retardada
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B15K Others concerning applications: alteration of classification

Ipc: A61K 45/06 (2006.01), A61P 31/00 (2006.01), A61P 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2670 DE 08-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.